-
KALA BIO | Stock Price Up Today 43%+, Get Ready For A Move
NASDAQ: KALA Introduction to KALA BIO and its recent stock performance Investors and traders have been closely monitoring the recent surge in KALA BIO’s stock price, which has seen a remarkable 43% increase. KALA BIO, a pharmaceutical company focused on developing innovative therapies, has captured the attention of the market with its promising advancements. In…
-
Vanda Pharmaceuticals | Announces U.S. FDA Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
NASDAQ: VNDA 1. Introduction to Vanda Pharmaceuticals’ new drug application for Tradipitant Vanda Pharmaceuticals, a leading biopharmaceutical company, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Tradipitant, a potential breakthrough treatment for gastroparesis. This acceptance marks a significant milestone in Vanda Pharmaceuticals’ efforts…
-
NeuroSense | Reporting Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
NASDAQ: NRSN Introduction NeuroSense, a groundbreaking biopharmaceutical company, is set to release the highly anticipated topline results of its Phase 2b clinical trial for ALS (Amyotrophic Lateral Sclerosis) on December 5, 2023. This milestone event marks a significant step forward in the search for new treatment options for this devastating disease. In this article, we…
-
RxE2 | Revolutionizes Clinical Trials with Groundbreaking AI-led Technology Platform and Marketplace
Introduction In the world of medical advancements, clinical trials play a crucial role in testing new drugs, treatments, and procedures to ensure their safety and efficacy. However, the traditional approach to conducting clinical trials is often time-consuming, costly, and resource-intensive. Enter RxE2, an innovative technology platform and marketplace that is revolutionizing the way clinical trials…
-
IDEAYA | Announces Agenda for Investor R&D Day Webcast on December 4, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company dedicated to the discovery and development of targeted therapeutics, is pleased to announce the agenda topics for its upcoming Investor R&D Day. This highly anticipated webcast event, hosted by IDEAYA, will take place on Monday, December 4, 2023, from 8:00 am to 9:30 am…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF DECEMBER 3-9, 2023
December 2, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE Conference 12/05/2023 JAGX 27.4 9,151 $0.36 Conference 12/07/2023 BMEA 43.2 25,780 $16.68 FDA Event 12/08/2023 BCLI 52.0 5,135 $0.26 Conference 12/09/2023 APTO 32.4 76 $2.66 Conference 12/09/2023 INCY 27.1 38,201 $54.02 WEEK: 12/03/2023 – 12/09/2023
-
Neurocrine Biosciences | Hosting Analyst Day on December 5, 2023
NASDAQ: $NBIX Neurocrine Biosciences to Host Analyst Day on December 5, 2023 Have you heard the news? Neurocrine Biosciences, a leading biopharmaceutical company, is set to host an Analyst Day on December 5, 2023. This highly anticipated event will bring together analysts, investors, and industry experts to explore Neurocrine Biosciences’ latest developments and future prospects.…
-
Intensity Therapeutics | Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
NASDAQ: INTS Intensity Therapeutics, a biotechnology company dedicated to developing innovative cancer therapies, has been selected to present at the prestigious Spotlight Oral Presentations. This recognition highlights the immense potential of the company’s scientific breakthroughs and further establishes its position as a leader in the field of oncology research. The selection also underscores the intelligence…
-
NeuroBo | Participating in Investor Conferences in December
NASDAQ: NRBO NeuroBo, a clinical-stage biotechnology company specializing in treatments for neurodegenerative diseases, has recently announced that it will be attending several investor conferences during the month of December. This move represents an exciting opportunity for the company to showcase its groundbreaking research and attract potential investors. With a focus on developing novel therapeutics for…
-
Jaguar Health | Presents December 5 at the MedInvest Oncology Investor Conference
Jaguar Health, a leading pharmaceutical company specializing in innovative treatments for various diseases, is set to present at the prestigious MedInvest Oncology Investor Conference on December 5. This highly anticipated event brings together top experts, investors, and industry leaders in the field of oncology. Jaguar Health’s participation at this conference is a testament to their…